Robust target assessment is essential to successful drug discovery, enabling confident prioritization of biologically relevant targets. At Axxam, we integrate AI-enabled target identification with experimental wet lab validation to support informed and early decision making.

Through our collaboration with Molecular Health, we apply advanced artificial intelligence and machine learning to analyze complex biomedical and clinical data, uncover disease mechanisms, and identify targets with strong translational potential. This data-driven approach improves target selection and reduces early-stage risk.